Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Baird Maintains Outperform on Marinus Pharma, Lowers Price Target to $24

Baird analyst Brian Skorney maintains Marinus Pharma (NASDAQ:MRNS) with a Outperform and lowers the price target from $32 to $24.
byBenzinga Newsdesk
November 9, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Baird analyst Brian Skorney maintains Marinus Pharma (NASDAQ:MRNS) with a Outperform and lowers the price target from $32 to $24.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0